China Shineway Pharmaceutical Group Limited reported no changes in its share capital structure for the month ended 31 March 2026, according to its latest monthly return filed with Hong Kong Exchanges and Clearing Limited on 1 April 2026.

• Authorised share capital remained at 5.00 billion ordinary shares with a par value of HKD 0.10, equivalent to HKD 500.00 million.

• Issued share capital was unchanged at 827.00 million ordinary shares; the company held no treasury shares during the month.

• There were no share option exercises, warrant conversions, convertible securities, or other equity-linked instruments outstanding or executed in March.

• The board confirmed full compliance with the Main Board’s minimum public-float requirement of 25% as at month-end.

The filing indicates a stable capital base, with no dilution or share repurchase activity in the reported period.